Effect of simvastatin treatment on plasma visfatin levels in obese women

References

• World Health Organization. Obesity: preventing and managing the global epidemic. Report of a World Health Organization Consultation. WHO Obesity Technical Report Series, n. 284. Geneva: World Health Organization; 2000
   Google Scholar
• Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 2005;115:911–19
   PubMed Web of Science ®Google Scholar
• Leite LD, Rocha ED, Brandão-Neto J. Obesidade: uma doença inflamatória. Revista Ciência & Saúde 2009;2:85–95
   Google Scholar
• Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005;307:426–30
   PubMed Web of Science ®Google Scholar
• Adya R, Tan BK, Punn A, et al. Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis. Cardiovasc Res 2008;78:356–65
   PubMed Web of Science ®Google Scholar
• Lovren F, Pan Y, Shukla PC, et al. Visfatin activates eNOS via Akt and MAP kinases and improves endothelial cell function and angiogenesis in vitro and in vivo: translational implications for atherosclerosis. Am J Physiol Endocrinol Metab 2009;296:E1440–9
   Google Scholar
• Xiao J, Xiao ZJ, Liu ZG, et al. Involvement of dimethylarginine dimethylaminohydrolase-2 in visfatin-enhanced angiogenic function of endothelial cells. Diabetes Metab Res 2009;25:242–9
   Web of Science ®Google Scholar
• Kim SR, Bae SK, Choi KS, et al. Visfatin promotes angiogenesis by activation of extracellular signal-regulated kinase 1/2. Biochem Biophys Res Commun 2007;357:150–6
   PubMed Web of Science ®Google Scholar
• Romacho T, Azcutia V, Vázquez-Bella M, et al. Extracellular PBEF/NAMPT/visfatin activates pro-inflammatory signalling in human vascular smooth muscle cells through nicotinamide phosphoribosyltransferase activity. Diabetologia 2009;52:2455–63
   PubMed Web of Science ®Google Scholar
• Galkina E, Ley K. Vascular adhesion molecules in atherosclerosis. Arterioscler Thromb Vasc Biol 2007;27:2292–301
   PubMed Web of Science ®Google Scholar
• Dahl TB, Yndestad A, Skjelland M, et al. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation 2007;115:972–80
   PubMed Web of Science ®Google Scholar
• Imai SI. Nicotinamide phosphoribosyltransferase (Nampt): a link between NAD biology, metabolism, and diseases. Curr Pharm Design 2009;15:20–8
   PubMed Web of Science ®Google Scholar
• Peiró C, Romacho T, Carraro R, Sánchez-Ferrer CF. Visfatin/PBEF/Nampt: a new cardiovascular target? Frontiers Pharmacol 2010;1:135
   PubMed Web of Science ®Google Scholar
• Mattu HS, Randeva HS. Role of adipokines in cardiovascular disease. J Endocrinol 2013;216:17–36
   PubMed Web of Science ®Google Scholar
• Kaminska A, Kopczyńska E, Bronisz A, et al. An evaluation of visfatin levels in obese subjects. Edokrynol Pol 2010;61:169–73
   PubMed Web of Science ®Google Scholar
• Haider DG, Schindler K, Schaller G, et al. Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J Clin Endocrinol Metab 2006;91:578–81
   Google Scholar
• Gargiulo G, Giugliano G, Brevetti L, et al. Use of statins in lower extremity artery disease: a review. BMC Surg 2012;1186:1471–2482
   Google Scholar
• Ridker PM, Rifai N, Pfeffer MA, et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 1999;100:230–5
   PubMed Web of Science ®Google Scholar
• Stogowska-Nikiciuk B, Malyszko J, Malyszko JS, et al. The influence of simvastatin on hsCRP and some paramneters of hemostasis in patients with ischemic heart disease. Przegl Lek 2008;65:68–72
   Google Scholar
• Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998;97:1129–35
   PubMed Web of Science ®Google Scholar
• Treasure C, Klein J. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995;332:481–7
   PubMed Web of Science ®Google Scholar
• Mihaylova B, Emberson J, Blackwell L, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012;380:581–90
   PubMed Web of Science ®Google Scholar
• Kaduglou PE, Vrabas IS, Kapelouzou A, et al. Impact of atorvastatin on serum vaspin levels in hypercholesterolemic patients with moderate cardiovascular risk. Regulatory Peptides 2011;170:57–61
   Google Scholar
• Pfutzner A, Hanefeld M, Lübben G, et al. Visfatin: a putative biomarker for metabolic syndrome is not influenced by pioglitazone or simvastatin treatment in nondiabetic patients at cardiovascular risk – results from the PIOSTAT study. Horm Metab Res 2007;39:764–8
   PubMedGoogle Scholar
• Kostapanos MS, Derdemezis CS, Filippatos TD, et al. Effect of rosuvastatin treatment on plasma visfatin levels in patients with primary hyperlipidemia. Eur J Pharmacol 2008;578:249–52
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Derdemezis CS, Kiortsis DN, et al. Increased plasma levels of visfatin/pre-B cell colony-enhancing factor in obese and overweight patients with metabolic syndrome. J Endocrinol Invest 2007;30:23–6
   Google Scholar
• Kostapanos MS, Liamis GL, Milionis HJ, et al. Do statins beneficially or adversely affect glucose homeostasis? Curr Vasc Pharmacol 2010;8:612–31
   PubMed Web of Science ®Google Scholar
• Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Retraction Science 2007;318:565
   PubMed Web of Science ®Google Scholar
• Koh K, Quon MJ, Han SH, et al. Simvastatin improves flow-mediated dilation but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients. Diabetes 2008;31:776–82
   Google Scholar
• Khan T, Hamilton MP, Mundy DI, et al. Impact of simvastatin on adipose tissue: pleiotropic effects in vivo. Endocrinology 2009;150:5262–72
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Randeva HS, Derdemezis CS, et al. Visfatin/PBEF and atherosclerosis-related diseases. Curr Vascular Pharmacol 2010;8:12–28
   PubMed Web of Science ®Google Scholar
• Pagano C, lon C, Olivieri M, et al. Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab 2006;91:3165–70
   PubMed Web of Science ®Google Scholar
• Korner A, Garten A, Blüher M, et al. Molecular characteristics of serum visfatin and differential detection by immunoassays. J Clin Endocrinol Metab 2007;92:4783–91
   PubMed Web of Science ®Google Scholar
• Uslu S, Kebapçi N, Kara M, et al. Relationship between adipocytokines and cardiovascular risk factors in patients with type 2 diabetes mellitus. Exp Therap Med 2012;4:113–20
   PubMed Web of Science ®Google Scholar
• Koh KK, Quon MJ, Han SH, et al. Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients. J Am College Cardiol 2010;55:1209–16
   PubMed Web of Science ®Google Scholar